Having already tested visiBIT at the Fehmarnbelt Tunnel, Northern Europe’s largest construction project, Visibuilt is now set to expand field trials and optimize its production process. This funding will support team expansion, research and development, and additional outdoor pilot projects. By integrating nature-inspired materials into road construction, Visibuilt aims to reduce the environmental impact of traditional asphalt.
The funding round includes contributions from leading biotech experts, including Steen Riisgaard, Per Falholt, David Kauffmann, and Thomas G. Schmidt. Together, these investors bring 150 years of experience in biotechnology, business development, and scaling green innovations, having played key roles in companies such as Novozymes (now Novonesis), AGC Biologics, and 21st.BIO.
Their strategic guidance will help Visibuilt refine its production model, strengthen its supply chain, and establish partnerships for large-scale field applications. The company also plans to expand its team to accelerate the commercialization of fungal-based asphalt binders.
CEO and Founder Line Kloster Pedersen emphasized that this funding milestone—combined with recent technical breakthroughs—positions Visibuilt to bring bio-based asphalt solutions to the global market.
EMDFonden, a Danish climate tech foundation focused on reducing global resource consumption, has also joined Visibuilt’s investor lineup. Known for its ownership of EMD International, a leader in renewable energy and district heating software, EMDFonden strategically invests in sustainable infrastructure solutions.
Board Chairman Frank Rosager highlighted that Visibuilt’s eco-friendly asphalt innovation aligns with EMDFonden’s mission to support low-carbon construction materials. This investment reflects the growing demand for biotech-driven alternatives to fossil-fuel-based road binders.
